NASDAQ: ASPIAsp Isotopes Inc Stock
$3.89+0.01 (+0.26%)
Updated Jul 20, 2026
ASPI Price
$3.89
Fair Value Price
N/A
Market Cap
$489.76M
52 Week Low
$3.61
52 Week High
$14.49
P/E
-1.87x
P/B
1.69x
P/S
19.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$26.93M
Earnings
-$173.52M
Gross Margin
17.6%
Operating Margin
-634.99%
Profit Margin
-644.4%
Debt to Equity
1
Operating Cash Flow
-$52M
Beta
2.01
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ASPI Overview
ASP Isotopes Inc. is an emerging advanced materials company, currently in its pre-commercial stage. This firm is dedicated to the comprehensive management of isotopes, encompassing their creation, dissemination, promotion, and eventual sale. The company's developmental portfolio includes Molybdenum-100, a non-radioactive isotope designed for medical applications, alongside Carbon-14 and Silicon-28. Furthermore, ASP Isotopes is involved with Uranium-235, a specific uranium isotope considered crucial for the carbon-free energy sector. Established in 2021, the company maintains its headquarters in Boca Raton, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ASPI's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Chemical
Industry Rating
B
ASPI
Ranked#11 of 11
Ranked#11 of 11
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.00 | A | |
| $46.16 | B | |
| $16.83 | B |
Be the first to know about important ASPI news, forecast changes, insider trades & much more!
ASPI News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ASPI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASPI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ASPI is poor value based on its book value relative to its share price (1.69x), compared to the US Chemicals industry average (1.52x)
P/B vs Industry Valuation
ASPI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ASPI due diligence checks available for Premium users.
Valuation
ASPI fair value
Fair Value of ASPI stock based on Discounted Cash Flow (DCF)
Price
$3.89
Fair Value
-$6.49
Undervalued by
159.94%
ASPI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ASPI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.87x
Industry
-16.92x
Market
11.71x
ASPI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.69x
Industry
1.52x
ASPI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ASPI's financial health
Profit margin
Revenue
$4.2M
Net Income
-$6.9M
Profit Margin
-164.5%
ASPI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ASPI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$587.7M
Liabilities
$288.7M
Debt to equity
1
ASPI's short-term assets ($308.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASPI's short-term assets ($308.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASPI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.8M
Investing
-$97.2M
Financing
$43.2M
ASPI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ASPI vs Chemical Stocks
Asp Isotopes Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.